Aerie Pharmaceuticals Inc. shares skyrocketed late Wednesday after the drug developer said its glaucoma treatment met its primary endpoint in a late-stage clinical trial. Aerie shares surged 70% to $30.59 on heavy volume. The company said its glaucoma treatment Rhopressa worked just as well as another treatment, timolol. Aerie said it expects to file a marketing application for Rhopressa with the Food and Drug Administration in mid-2016.
Copyright © 2015 MarketWatch, Inc.
Continue Reading Below